Hepatic encephalopathy: A primary neurogliopathy

Sharon DeMorrow, Roger F. Butterworth

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hepatic encephalopathy (HE) and brain edema are serious central nervous complications of both acute and chronic liver failure. HE starts as a neuropsychiatric syndrome beginning with changes in personality and sleep disturbances progressing through cognitive dysfunction and motor symptoms to stupor and coma. In acute liver failure (ALF) progression may be very rapid, sometimes of the order of days (Butterworth and Vaquero, The liver; biology and pathobiology, pp. 600-617, 2009). Since the appearance of overt signs of encephalopathy in liver failure generally heralds a poor prognosis with a significant impact on clinical management options, on liver transplant outcome and on health-related quality of life, rational effective therapies are urgently required. Such therapies require knowledge of the precise mechanisms implicated in the pathogenesis of HE.

Original languageEnglish (US)
Title of host publicationPathological Potential of Neuroglia
Subtitle of host publicationPossible New Targets for Medical Intervention
PublisherSpringer New York
Pages351-372
Number of pages22
ISBN (Electronic)9781493909742
ISBN (Print)1493909738, 9781493909735
DOIs
StatePublished - Mar 1 2014

Fingerprint

Hepatic Encephalopathy
Acute Liver Failure
Stupor
End Stage Liver Disease
Liver
Brain Edema
Liver Failure
Brain Diseases
Coma
Personality
Sleep
Quality of Life
Transplants
Therapeutics

Keywords

  • Alzheimer type 2 astrocytosis
  • Brain edema
  • Chemokines
  • Cirrhosis
  • Hepatic encephalopathy
  • Liver failure
  • Microglial activation
  • Minocycline

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

DeMorrow, S., & Butterworth, R. F. (2014). Hepatic encephalopathy: A primary neurogliopathy. In Pathological Potential of Neuroglia: Possible New Targets for Medical Intervention (pp. 351-372). Springer New York. https://doi.org/10.1007/978-1-4939-0974-2-15

Hepatic encephalopathy : A primary neurogliopathy. / DeMorrow, Sharon; Butterworth, Roger F.

Pathological Potential of Neuroglia: Possible New Targets for Medical Intervention. Springer New York, 2014. p. 351-372.

Research output: Chapter in Book/Report/Conference proceedingChapter

DeMorrow, S & Butterworth, RF 2014, Hepatic encephalopathy: A primary neurogliopathy. in Pathological Potential of Neuroglia: Possible New Targets for Medical Intervention. Springer New York, pp. 351-372. https://doi.org/10.1007/978-1-4939-0974-2-15
DeMorrow S, Butterworth RF. Hepatic encephalopathy: A primary neurogliopathy. In Pathological Potential of Neuroglia: Possible New Targets for Medical Intervention. Springer New York. 2014. p. 351-372 https://doi.org/10.1007/978-1-4939-0974-2-15
DeMorrow, Sharon ; Butterworth, Roger F. / Hepatic encephalopathy : A primary neurogliopathy. Pathological Potential of Neuroglia: Possible New Targets for Medical Intervention. Springer New York, 2014. pp. 351-372
@inbook{f1c687299519428a9410567054590d86,
title = "Hepatic encephalopathy: A primary neurogliopathy",
abstract = "Hepatic encephalopathy (HE) and brain edema are serious central nervous complications of both acute and chronic liver failure. HE starts as a neuropsychiatric syndrome beginning with changes in personality and sleep disturbances progressing through cognitive dysfunction and motor symptoms to stupor and coma. In acute liver failure (ALF) progression may be very rapid, sometimes of the order of days (Butterworth and Vaquero, The liver; biology and pathobiology, pp. 600-617, 2009). Since the appearance of overt signs of encephalopathy in liver failure generally heralds a poor prognosis with a significant impact on clinical management options, on liver transplant outcome and on health-related quality of life, rational effective therapies are urgently required. Such therapies require knowledge of the precise mechanisms implicated in the pathogenesis of HE.",
keywords = "Alzheimer type 2 astrocytosis, Brain edema, Chemokines, Cirrhosis, Hepatic encephalopathy, Liver failure, Microglial activation, Minocycline",
author = "Sharon DeMorrow and Butterworth, {Roger F.}",
year = "2014",
month = "3",
day = "1",
doi = "10.1007/978-1-4939-0974-2-15",
language = "English (US)",
isbn = "1493909738",
pages = "351--372",
booktitle = "Pathological Potential of Neuroglia",
publisher = "Springer New York",
address = "United States",

}

TY - CHAP

T1 - Hepatic encephalopathy

T2 - A primary neurogliopathy

AU - DeMorrow, Sharon

AU - Butterworth, Roger F.

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Hepatic encephalopathy (HE) and brain edema are serious central nervous complications of both acute and chronic liver failure. HE starts as a neuropsychiatric syndrome beginning with changes in personality and sleep disturbances progressing through cognitive dysfunction and motor symptoms to stupor and coma. In acute liver failure (ALF) progression may be very rapid, sometimes of the order of days (Butterworth and Vaquero, The liver; biology and pathobiology, pp. 600-617, 2009). Since the appearance of overt signs of encephalopathy in liver failure generally heralds a poor prognosis with a significant impact on clinical management options, on liver transplant outcome and on health-related quality of life, rational effective therapies are urgently required. Such therapies require knowledge of the precise mechanisms implicated in the pathogenesis of HE.

AB - Hepatic encephalopathy (HE) and brain edema are serious central nervous complications of both acute and chronic liver failure. HE starts as a neuropsychiatric syndrome beginning with changes in personality and sleep disturbances progressing through cognitive dysfunction and motor symptoms to stupor and coma. In acute liver failure (ALF) progression may be very rapid, sometimes of the order of days (Butterworth and Vaquero, The liver; biology and pathobiology, pp. 600-617, 2009). Since the appearance of overt signs of encephalopathy in liver failure generally heralds a poor prognosis with a significant impact on clinical management options, on liver transplant outcome and on health-related quality of life, rational effective therapies are urgently required. Such therapies require knowledge of the precise mechanisms implicated in the pathogenesis of HE.

KW - Alzheimer type 2 astrocytosis

KW - Brain edema

KW - Chemokines

KW - Cirrhosis

KW - Hepatic encephalopathy

KW - Liver failure

KW - Microglial activation

KW - Minocycline

UR - http://www.scopus.com/inward/record.url?scp=84929845266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929845266&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-0974-2-15

DO - 10.1007/978-1-4939-0974-2-15

M3 - Chapter

AN - SCOPUS:84929845266

SN - 1493909738

SN - 9781493909735

SP - 351

EP - 372

BT - Pathological Potential of Neuroglia

PB - Springer New York

ER -